First and Only Topical Gel Provides Ease, Efficacy and Excellent Tolerability CORONA, Calif., Jan. 27 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE ...

The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...

Uncontrolled glaucoma. GI obstruction. Paralytic ileus. Intestinal atony in elderly or debilitated. Severe colitis. Myasthenia gravis. Megacolon. Toxic megacolon in ulcerative colitis. Obstructive ...

February 2, 2009 — On January 27, Watson Pharmaceuticals, Inc, announced that the US Food and Drug Administration (FDA) has approved oxybutynin chloride gel 10% (Gelnique) for the treatment of ...

Details concerning the Oxybutynin Chloride combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, ...

Company's step-down wholly owned subsidiary Strides Pharma Global Pte Ltd, Singapore, has received approval for Oxybutynin Chloride Tablets USP, 5 mg from the United States Food & Drug Administration ...

OAKVILLE, ON, Sept. 12, 2012 /CNW/ - Watson Canada today announced that Gelnique® (oxybutynin chloride gel), the first-ever topical gel for the treatment of overactive bladder (OAB), is now available ...

A unit of Zydus Lifesciences is recalling more than 7,000 bottles of Oxybutynin Chloride tablets in the U.S. due to manufacturing issues, according to the U.S. Food and Drug Administration (FDA). As ...

Drug firm Strides Pharma Science on Friday said its Singapore-based arm has received approval from the US health regulator for generic Oxybutynin Chloride tablets used to treat symptoms of overactive ...

New Jersey-based Zydus Pharmaceuticals (USA) Inc. is recalling the affected lot due to "Failed Dissolution Specifications", the USFDA stated. The lot was produced at Ahmedabad and distributed in the ...